Literature DB >> 33362486

Role of Nuclear Imaging to Understand the Neural Substrates of Brain Disorders in Laboratory Animals: Current Status and Future Prospects.

Annunziata D'Elia1,2, Sara Schiavi2, Andrea Soluri1, Roberto Massari1, Alessandro Soluri1, Viviana Trezza2.   

Abstract

Molecular imaging, which allows the real-time visualization, characterization and measurement of biological processes, is becoming increasingly used in neuroscience research. Scintigraphy techniques such as single photon emission computed tomography (SPECT) and positron emission tomography (PET) provide qualitative and quantitative measurement of brain activity in both physiological and pathological states. Laboratory animals, and rodents in particular, are essential in neuroscience research, providing plenty of models of brain disorders. The development of innovative high-resolution small animal imaging systems together with their radiotracers pave the way to the study of brain functioning and neurotransmitter release during behavioral tasks in rodents. The assessment of local changes in the release of neurotransmitters associated with the performance of a given behavioral task is a turning point for the development of new potential drugs for psychiatric and neurological disorders. This review addresses the role of SPECT and PET small animal imaging systems for a better understanding of brain functioning in health and disease states. Brain imaging in rodent models faces a series of challenges since it acts within the boundaries of current imaging in terms of sensitivity and spatial resolution. Several topics are discussed, including technical considerations regarding the strengths and weaknesses of both technologies. Moreover, the application of some of the radioligands developed for small animal nuclear imaging studies is discussed. Then, we examine the changes in metabolic and neurotransmitter activity in various brain areas during task-induced neural activation with special regard to the imaging of opioid, dopaminergic and cannabinoid receptors. Finally, we discuss the current status providing future perspectives on the most innovative imaging techniques in small laboratory animals. The challenges and solutions discussed here might be useful to better understand brain functioning allowing the translation of preclinical results into clinical applications.
Copyright © 2020 D'Elia, Schiavi, Soluri, Massari, Soluri and Trezza.

Entities:  

Keywords:  PET - positron emission tomography; SPECT; behavioral neuroscience; brain disorders; neuroimaging; small animal imaging

Year:  2020        PMID: 33362486      PMCID: PMC7759612          DOI: 10.3389/fnbeh.2020.596509

Source DB:  PubMed          Journal:  Front Behav Neurosci        ISSN: 1662-5153            Impact factor:   3.558


  196 in total

Review 1.  Small-animal positron emission tomography as a tool for neuropharmacology.

Authors:  Sophie Lancelot; Luc Zimmer
Journal:  Trends Pharmacol Sci       Date:  2010-07-06       Impact factor: 14.819

Review 2.  Small-animal SPECT and SPECT/CT: important tools for preclinical investigation.

Authors:  Benjamin L Franc; Paul D Acton; Carina Mari; Bruce H Hasegawa
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

Review 3.  Positron emission tomography in CNS drug discovery and drug monitoring.

Authors:  Markus Piel; Ingo Vernaleken; Frank Rösch
Journal:  J Med Chem       Date:  2014-09-10       Impact factor: 7.446

4.  Design and evaluation of two multi-pinhole collimators for brain SPECT.

Authors:  Ling Chen; Benjamin M W Tsui; Greta S P Mok
Journal:  Ann Nucl Med       Date:  2017-07-28       Impact factor: 2.668

Review 5.  Standardization of Small Animal Imaging-Current Status and Future Prospects.

Authors:  Julia G Mannheim; Firat Kara; Janine Doorduin; Kerstin Fuchs; Gerald Reischl; Sayuan Liang; Marleen Verhoye; Felix Gremse; Laura Mezzanotte; Marc C Huisman
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

6.  Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease.

Authors:  D M Araujo; S R Cherry; K J Tatsukawa; T Toyokuni; H I Kornblum
Journal:  Exp Neurol       Date:  2000-12       Impact factor: 5.330

7.  [18F]FMPEP-d2 PET imaging shows age- and genotype-dependent impairments in the availability of cannabinoid receptor 1 in a mouse model of Alzheimer's disease.

Authors:  Jatta S Takkinen; Francisco R López-Picón; Anna K Kirjavainen; Rea Pihlaja; Anniina Snellman; Tamiko Ishizu; Eliisa Löyttyniemi; Olof Solin; Juha O Rinne; Merja Haaparanta-Solin
Journal:  Neurobiol Aging       Date:  2018-05-18       Impact factor: 4.673

8.  PET Imaging of Angiogenesis.

Authors:  Gang Niu; Xiaoyuan Chen
Journal:  PET Clin       Date:  2009-01-01

9.  Advances in cardiac PET/MR imaging: Facilitating cutting-edge structural and biological phenotyping of the cardiovascular system.

Authors:  Ahmed Tawakol; Georges El Fakhri; Ciprian Catana; David E Sosnovik
Journal:  J Nucl Cardiol       Date:  2020-03-03       Impact factor: 5.952

Review 10.  Imaging of opioid receptors in the central nervous system.

Authors:  Gjermund Henriksen; Frode Willoch
Journal:  Brain       Date:  2007-11-29       Impact factor: 13.501

View more
  2 in total

Review 1.  Application of Advanced Imaging Modalities in Veterinary Medicine: A Review.

Authors:  Dagmawi Yitbarek; Gashaw Getaneh Dagnaw
Journal:  Vet Med (Auckl)       Date:  2022-05-31

2.  Performance evaluation of the IRIS XL-220 PET/CT system, a new camera dedicated to non-human primates.

Authors:  Frédéric Boisson; Sophie Serriere; Liji Cao; Sylvie Bodard; Alessandro Pilleri; Lionel Thomas; Giancarlo Sportelli; Johnny Vercouillie; Patrick Emond; Clovis Tauber; Nicola Belcari; Jean-Luc Lefaucheur; David Brasse; Laurent Galineau
Journal:  EJNMMI Phys       Date:  2022-02-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.